STOCK TITAN
  1. Home
  2. Sec-filings
  3. URGN
  4. [Form 4] UroGen Pharma Ltd. Insider Trading Activity

UroGen Pharma (URGN) director awarded 8,000 RSUs and 10,000 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

UroGen Pharma Ltd. director James A. Robinson Jr. reported equity awards that increase his potential ownership in the company. On June 22, 2026, he received 8,000 restricted stock units (RSUs), each representing one ordinary share upon vesting. He was also granted stock options on 10,000 ordinary shares with an exercise price of $34.99 per share and an expiration date of June 22, 2036. Both the RSUs and the option shares vest in equal quarterly installments over one year, contingent on his continued board service. After these grants, his reported holdings from these awards are 8,000 RSUs and 10,000 options, reflecting routine director compensation rather than open‑market trading.

Positive

  • None.

Negative

  • None.
Insider Robinson James A. Jr.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right ot buy) 10,000 $0.00 --
Grant/Award Restricted Stock Unit 8,000 $0.00 --
Holdings After Transaction: Stock Option (right ot buy) — 10,000 shares (Direct, null); Restricted Stock Unit — 8,000 shares (Direct, null)
Footnotes (1)
  1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
RSUs granted 8,000 units Restricted stock units granted on June 22, 2026
Options granted 10,000 options Stock options granted on June 22, 2026
Option exercise price $34.99 per share Exercise price for 10,000 stock options
Option expiration June 22, 2036 Expiration date of the stock options
RSU underlying shares 8,000 ordinary shares Each RSU converts into one ordinary share upon vesting
Option underlying shares 10,000 ordinary shares Shares purchasable upon exercising the options
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option financial
"The shares underlying the stock option will vest in equal quarterly installments"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Continuous Service financial
"subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan)"
2017 Equity Incentive Plan financial
"as defined in the 2017 Equity Incentive Plan through such vesting dates"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Robinson James A. Jr.
(Last)(First)(Middle)
400 ALEXANDER PARK DRIVE
(Street)
PRINCETON NEW JERSEY 08540
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right ot buy)$34.9906/22/2026A10,000 (1)06/22/2036Ordinary Shares10,000$010,000D
Restricted Stock Unit(2)06/22/2026A8,000 (3) (3)Ordinary Shares8,000$08,000D
Explanation of Responses:
1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
/s/ Jason D. Smith, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did UroGen Pharma (URGN) director James A. Robinson Jr. receive in this Form 4?

He received equity-based compensation: 8,000 restricted stock units and 10,000 stock options. These awards give him potential future ownership in UroGen Pharma, subject to vesting conditions and, for options, paying the stated exercise price.

How many restricted stock units were granted to the UroGen Pharma (URGN) director?

He was granted 8,000 restricted stock units. Each RSU represents a contingent right to receive one ordinary share of UroGen Pharma, delivered only as the units vest over time under the company’s equity plan.

What are the key terms of the stock options granted to the UroGen Pharma (URGN) director?

He received options on 10,000 ordinary shares at an exercise price of $34.99, expiring June 22, 2036. The options vest in equal quarterly installments over one year, conditioned on his continuous service as a director.

How do the RSUs for UroGen Pharma (URGN) vest for the director?

The 8,000 RSUs vest in equal quarterly installments over one year. Vesting depends on the director maintaining “Continuous Service” under UroGen Pharma’s 2017 Equity Incentive Plan through each scheduled vesting date.

Are these UroGen Pharma (URGN) insider transactions open-market buys or sales?

They are not open-market trades. The Form 4 shows compensation-related grants coded as “A,” meaning awards of RSUs and stock options from the company, rather than purchases or sales on the stock market.

What does each UroGen Pharma (URGN) RSU represent for the director?

Each restricted stock unit represents a contingent right to receive one ordinary share of UroGen Pharma. The director only receives the actual shares as the RSUs vest under the plan’s service-based conditions.